• Mac-1 Deficiency Reduces Cardiac Remodeling via Macrophage M

  2026-05-07

  This study demonstrates that Mac-1 deficiency significantly ameliorates cardiac dysfunction and pathological remodeling under pressure overload by inhibiting macrophage infiltration and M1 polarization. The findings identify Mac-1 as a promising target for therapeutic intervention in heart failure and highlight the importance of immune signaling pathways in cardiac disease.

• Morin: Applied Workflows and Troubleshooting in Disease Mode

  2026-05-07

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a high-purity natural flavonoid that excels as both a mechanistic probe in diabetes and neuroprotection studies and a fluorescent chelator for aluminum detection. This guide translates leading-edge research and protocol insights into actionable workflows, troubleshooting strategies, and advanced use-cases for Morin in translational disease research.

• Polymyxin B (sulfate): Reliable Solutions for Advanced Lab A

  2026-05-06

  This article addresses critical laboratory challenges in cell-based infection and immunomodulation assays, illustrating how Polymyxin B (sulfate) (SKU C3090) from APExBIO offers reliable, data-backed performance. Through real-world scenarios, we clarify protocol optimization, product selection, and data interpretation, ensuring reproducibility and scientific rigor for biomedical researchers.

• ALDOB K87 Lactylation and Mitochondrial Dynamics in Pulmonar

  2026-05-06

  This article reviews new evidence that ALDOB K87 lactylation drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension by recruiting DRP1 to mitochondria. These insights clarify mechanisms of smooth muscle cell proliferation and suggest new avenues for therapeutic intervention.

• Disulfiram (SKU A4015): Reliable Tool for Apoptosis & Protea

  2026-05-05

  This scenario-driven article explores how Disulfiram (SKU A4015) addresses persistent challenges in cell viability, proliferation, and synthetic lethality assays. By integrating recent evidence and best-practice protocols, it demonstrates how APExBIO’s Disulfiram offers reproducible, data-backed solutions for cancer research workflows.

• Verteporfin (CL 318952): Mechanotransduction, Chemoresistanc

  2026-05-05

  Explore Verteporfin (CL 318952) as more than a photosensitizer—delve into its role in mechanotransduction, chemoresistance, and advanced photodynamic therapy assays. Unique analysis links the tumor microenvironment’s mechanics with Verteporfin’s action, offering new directions for age-related macular degeneration and drug resistance research.

• VX-661 F508del CFTR Corrector: Optimizing Cystic Fibrosis Re

  2026-05-04

  VX-661 (F508del CFTR corrector) enables precise modulation of CFTR trafficking and function for cystic fibrosis research. This guide delivers actionable, variant-responsive workflows, troubleshooting tips, and calnexin-informed strategies that set your experiments apart.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: CDCA Mechani

  2026-05-04

  This study reveals that Chenodeoxycholic Acid (CDCA) activates the farnesoid X receptor (FXR), leading to transcriptional upregulation of KLF11 and suppression of the JAK2/STAT3 pathway. The findings define the FXR-KLF11 axis as a mechanistic target for preventing contrast-induced acute kidney injury (CI-AKI), supporting the use of FXR agonists in renal protection strategies.

• Novobiocin’s Inhibition of Membrane and Vacuole Formation in

  2026-05-03

  This study reveals that Novobiocin Sodium, an aminocoumarin antibiotic, blocks both membrane synthesis and vacuole formation in Enterococcus faecalis protoplasts by inhibiting DNA replication. These findings clarify the coupling between DNA synthesis and organelle biogenesis in bacterial cell models, providing a refined experimental tool for cell cycle and DNA damage studies.

• Hexa-acylated LPS Shapes Immunotherapy via TLR4 Modulation

  2026-05-02

  This study reveals that gut microbiota-derived hexa-acylated lipopolysaccharides (LPS) enhance anti-PD-1 immunotherapy responses by activating the TLR4 pathway. The findings clarify the structural specificity of LPS in modulating antitumor immunity, with practical implications for microbiome-informed cancer immunotherapy strategies.

• Substance P in Bioaerosol Detection: New Frontiers in Resear

  2026-05-01

  Explore how Substance P, a key tachykinin neuropeptide, is advancing bioaerosol detection and toxicology research. This article reveals novel applications grounded in fluorescence spectroscopy and bridges neurobiology with environmental health.

• BAPTA Calcium Chelator: Applied Workflows in Apoptosis and C

  2026-05-01

  BAPTA stands out as a high-affinity calcium chelator for dissecting complex calcium-dependent pathways in apoptosis and cell signaling studies. This article details experimental workflows, troubleshooting strategies, and protocol enhancements, leveraging both recent environmental toxicology findings and rigorous assay design to maximize research reproducibility.

• Recombinant Human Growth Hormone in IGF-1 Pathway Research

  2026-04-30

  Unlock reproducible IGF-1 pathway interrogation with APExBIO’s Recombinant Human Growth Hormone (GH), validated for high-potency cell signaling studies. This guide distills advanced workflows, troubleshooting strategies, and unique mechanistic insights for bone growth and chondrocyte biology models.

• Biomimetic Nanoparticles Mitigate Ovarian Inflammation via N

  2026-04-30

  This study introduces a biomimetic nanoparticle system for targeted delivery of α-cyperone to granulosa cells, effectively reducing LPS-induced inflammation and oxidative stress through Nrf2/HO-1 pathway activation. The approach offers a significant advance in potential therapies for diminished ovarian reserve, highlighting the synergistic role of nanotechnology and molecular targeting in reproductive medicine.

• Mubritinib (TAK 165): Rethinking OXPHOS in Virus-Driven Canc

  2026-04-29

  This thought-leadership article explores Mubritinib (TAK 165) as a transformative tool for translational researchers, highlighting its unique mechanism as a mitochondrial complex I inhibitor with selectivity for chemotherapy-resistant AML and KSHV-driven primary effusion lymphoma (PEL). By integrating mechanistic insights, experimental best practices, and strategic perspectives, we provide a roadmap for leveraging Mubritinib in advanced oncology and virology research. The article critically analyzes recent findings, protocol optimizations, and the evolving competitive landscape, offering actionable guidance and a forward-looking outlook for translational applications.

3640 records 13/243 page Previous Next First page 上5页 1112131415 下5页 Last page